Type I Diabetes

27 registered clinical trials studyying Type I Diabetes — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Food is Medicine in Pediatric Patients With Diabetes NCT07535502	University of Massachusetts, Worcester	N/A
Recruiting	Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus NCT06964087	Op-T LLC	Phase 2
Recruiting	Clinical Evaluation of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in Adult Subjects With Type NCT06739811	Medtronic MiniMed, Inc.	N/A
Completed	How Type I Diabetes Responds to Different Diets (Normoglucidic or Ketogenic) During Physical Activity at Altit NCT06242548	Centre Hospitalier Metropole Savoie	N/A
Completed	Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life O NCT06674135	Life for a Child Program, Diabetes Australia	Phase 4
Completed	Type 1 Diabetic Post Prandial Glycemia Evaluation Using an Algorithm NCT05151770	M-DT1	—
Withdrawn	Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes NCT05035368	Dompé Farmaceutici S.p.A	Phase 2
Completed	A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 NCT04279613	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1
Completed	Diabetes Inspired Culinary Education NCT05160142	Case Western Reserve University	EARLY_Phase 1
Terminated	Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump NCT03653533	ARAIR Assistance	N/A
Completed	Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects NCT01843114	Medical University of Vienna	N/A
Completed	Effects of Capros in Patients With Type-1 Diabetes NCT02634216	Ohio State University	N/A
Completed	The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Di NCT02002130	University of Alabama at Birmingham	Phase 1
Unknown	Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients NCT02117518	Migal Galilee Research Institute	—
Completed	A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients Wi NCT01928329	Yale University	Phase 2
Withdrawn	Epigenetic Modifications of Diabetes Mellitus Type I NCT01623388	Scripps Translational Science Institute	—
Completed	The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy NCT02127762	Ottawa Hospital Research Institute	N/A
Terminated	A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation NCT01652911	University of Alberta	Phase 1 / Phase 2
Withdrawn	Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes NCT01477476	University of Colorado, Denver	Phase 2
Withdrawn	Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics NCT01398670	Wockhardt	Phase 3
Terminated	Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics NCT01308437	Wockhardt	Phase 3
Completed	Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF) NCT00999375	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2
Withdrawn	Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device NCT00361608	EarlySense Ltd.	—
Completed	Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan NCT00351650	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	—
Completed	Obesity and Metabolic Surgery in Patients With Type I Diabetes NCT02612493	Sana Klinikum Offenbach	—
Completed	Management of Type 1 Diabetes Among Adolescents NCT00340639	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	—
Withdrawn	Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients NCT01352663	Wockhardt	Phase 3